½ÃÀ庸°í¼­
»óǰÄÚµå
1611805

¼¼°èÀÇ ¼³Æù¾Æ¹Ìµå ½ÃÀå : ÇüÅÂ, Åõ¿© °æ·Î, À¯Åë ä³Î, ¿ëµµº° ¿¹Ãø(2025-2030³â)

Sulphonamides Market by Form (Capsule, Liquid, Powder), Route of Administration (Oral, Topical), Distribution Channel, Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼³Æù¾Æ¹Ìµå ½ÃÀåÀº 2023³â¿¡ 1¾ï 344¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 1¾ï 852¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 5.79%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1¾ï 5,343¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÇÕ¼º Ç×±ÕÁ¦ÀÇ ÀÏÁ¾ÀÎ ¼³Æù¾Æ¹Ìµå´Â ±× ±¤¹üÀ§ÇÑ Ç×±Õ Æ¯¼º¿¡ ÀÇÇØ Á¦¾à ¾÷°è¿¡¼­ Áß¿äÇÑ Æ´»õ¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.ÀüÅëÀûÀ¸·Î ¼¼±Õ °¨¿°ÁõÀÇ Ä¡·á¿¡ »ç¿ëµÇ¾î ¿Â ÀÌ Ç×±ÕÁ¦´Â ¼¼±ÕÀÇ ¿±»ê ÇÕ¼ºÀ» ¾ïÁ¦ÇÏ°í ¼¼±ÕÀÇ Áõ½Ä ´É·ÂÀ» ÀúÇϽÃÅ´À¸·Î½á È¿°ú¸¦ ¹ßÈÖÇÕ´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼¼°è ¼¼±Õ °¨¿°ÀÇ Áö¼ÓÀûÀÎ À§Çù¿¡ ÀÇÇØ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. µÎµå·¯Áö°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ´Â Á¦¾à ȸ»ç, µ¿¹° º´¿ø, »õ·Î¿î Ç×±Õ Àü·«ÀÇ °³¹ß¿¡ ÁÖ·ÂÇÏ´Â ¿¬±¸ ±â°ü µî ´Ù¹æ¸é¿¡ °ÉĨ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 1¾ï 344¸¸ ´Þ·¯
¿¹Ãø³â(2024) 1¾ï 852¸¸ ´Þ·¯
¿¹Ãø³â(2030) 1¾ï 5,343¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 5.79%

¼úÆù ¾Æ¹Ìµå ½ÃÀå ¼ºÀåÀº °¨¿°Áõ Áõ°¡¿Í Ç×±ÕÁ¦ ³»¼ºÀÌ ³ô¾ÆÁö´Â °¡¿îµ¥ È¿°úÀûÀÎ Ç×»ýÁ¦ÀÇ ±ä±Þ ¿ä±¸°¡ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¾Æ½Ã¾Æ¿Í ¾ÆÇÁ¸®Ä«ÀÇ ½ÅÈï ½ÃÀåÀº ÇコÄɾî ÅõÀÚ Áõ°¡¿Í °¨¿°ÀÇ ¸¸¿¬À¸·Î ÀÎÇØ Å« ºñÁî´Ï½º ±âȸ°¡µÇ¾ú½À´Ï´Ù. ±×¸®°í ½ÃÀåÀº ±ÔÁ¦»óÀÇ Àå¾Ö¹°°ú ºÎÀÛ¿ëÀÌ ÀûÀº ½ÅÇü Ç×»ýÁ¦¿Í °°Àº ´ëüǰÀÇ À§Çù°ú °°Àº °úÁ¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ¿µÇâ¿¡ ´ëÇÑ »çȸÀû ¿ì·Á°¡ ±× º¸±Þ¿¡ Á¦¾àÀ» °¡Á®¿Ô½À´Ï´Ù.

Çõ½Å°ú ¿¬±¸´Â ¸Å¿ì Áß¿äÇϸç, ³»¼º ¹ßÇöÀ» ÃÖ¼ÒÈ­Çϸ鼭 À¯È¿¼ºÀ» À¯ÁöÇÏ´Â °³·®Çü ¼³Æù¾Æ¹ÌµåÀÇ °³¹ß¿¡ À־, ºñ¾àÀûÀÎ Áøº¸¸¦ ÀÌ·ê °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. Ä¡·á Áö¼ö°¡ Çâ»ó µÉ ¼ö ÀÖ½À´Ï´Ù. ÇØ°áÃ¥¿¡ ´ëÇÑ ¿ä±¸°¡ Áö¼ÓµÊ¿¡ µû¶ó ³·Àº ³»¼º À§ÇèÀÇ Ç×»ýÁ¦¸¦ ÇâÇÑ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ°¡ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ »óȲÀ» ±Øº¹Çϱâ À§ÇØ Á¤ºÎ º¸°Ç±â±¸¿Í Á¦ÈÞÇØ¾ß ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¼³Æù¾Æ¹Ìµå ½ÃÀå¿¡¼­ Áß¿äÇÑ ½ÃÀå ÀλçÀÌÆ®ÀÇ ÇØ¸í

¼³Æù¾Æ¹Ìµå ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ±×¸®°í »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇØ ´õ ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°èÀÇ ¸¸¼ºÁúȯÀÇ ¸¸¿¬
    • ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ ¼³Æù¾Æ¹Ìµå Á¦Á¦ÀÇ ´ëÆøÀûÀÎ À̿밡´É¼º
    • ¼³ÆÄ Á¦Á¦¿Í ±× Ä¡·á ¿ëµµ¿¡ °üÇÑ ÀνÄ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼³Æù¾Æ¹ÌµåÀÇ ºÎÀÛ¿ë
  • ½ÃÀå ±âȸ
    • Á¦¾à±â¾÷¿¡¼­ÀÇ ¿¬±¸°³¹ß Áõ°¡
    • ÀÇ·á °ü±¤ »ê¾÷ÀÇ ±Þ¼ÓÇÑ ¹ßÀü
  • ½ÃÀåÀÇ °úÁ¦
    • ½ÅÈï±¹¿¡¼­ÀÇ ±ÔÁ¦ üÁ¦ÀÇ ºÎÁ·

Porter's Five Forces ¼úÆù ¾Æ¹Ìµå ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϰí ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÔÀ¸·Î½á º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¼úÆù ¾Æ¹Ìµå ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¼³Æù ¾Æ¹Ìµå ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ °¡´ÉÇÕ´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¼úÆù ¾Æ¹Ìµå ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

¼úÆù ¾Æ¹Ìµå ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¼³Æù ¾Æ¹Ìµå ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¼³Æù ¾Æ¹Ìµå ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå ¼úÆù ¾Æ¹Ìµå ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

¼³Æù¾Æ¹Ìµå ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼°è¿¡¼­ ¸¸¼ºÁúȯÀÇ ÀÌȯÀ²ÀÌ Áõ°¡
      • ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ ¼úÆù ¾Æ¹Ìµå Á¦Á¦ÀÇ ÃæºÐÇÑ °¡¿ë¼º
      • ¼³ÆÄÁ¦¿Í ±× Ä¡·á ¿ëµµ¿¡ °üÇÑ ÀνÄ
    • ¾ïÁ¦¿äÀÎ
      • ¼³Æù¾Æ¹ÌµåÀÇ ºÎÀÛ¿ë
    • ±âȸ
      • Á¦¾àȸ»çÀÇ ¿¬±¸°³¹ß Áõ°¡
      • ±Þ¼ÓÈ÷ ¹ßÀüÇÏ´Â ÀÇ·á°ü±¤»ê¾÷
    • °úÁ¦
      • ½ÅÈï °æÁ¦¿¡¼­ ±ÔÁ¦ ±¸Á¶ÀÇ ºÎÁ·
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ¼³Æù¾Æ¹Ìµå ½ÃÀå : Çüź°

  • ĸ½¶
  • ¾×ü
  • ºÐ¸»
  • ÅÂºí¸´

Á¦7Àå ¼³Æù¾Æ¹Ìµå ½ÃÀå : Åõ¿© °æ·Îº°

  • ±¸°­
  • È­Á¦

Á¦8Àå ¼³Æù¾Æ¹Ìµå ½ÃÀå : À¯Åëä³Îº°

  • ¿Â¶óÀÎ ½ºÅä¾î ¼Ò¸Å¾÷ü
  • Á¡Æ÷Çü ¼Ò¸Å¾÷ü

Á¦9Àå ¼³Æù¾Æ¹Ìµå ½ÃÀå : ¿ëµµº°

  • ¼ÒÈ­°ü °¨¿°Áõ
  • È£Èí±â °¨¿°Áõ
  • ÇǺΠ°¨¿°Áõ
  • ¿ä·Î °¨¿°Áõ

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¼³Æù¾Æ¹Ìµå ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼³Æù¾Æ¹Ìµå ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¼³Æù¾Æ¹Ìµå ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • AA Pharma Inc.
  • Abbott Laboratories
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Cadila Pharmaceuticals Ltd.
  • Cipla Ltd.
  • F. Hoffmann La Roche Ltd.
  • Fera Science Limited
  • GlaxoSmithKline PLC
  • NorthStar Rx LLC
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
BJH 24.12.24

The Sulphonamides Market was valued at USD 103.44 million in 2023, expected to reach USD 108.52 million in 2024, and is projected to grow at a CAGR of 5.79%, to USD 153.43 million by 2030.

Sulphonamides, a class of synthetic antimicrobial agents, occupy a significant niche in the pharmaceutical industry due to their broad-spectrum antibacterial properties. Traditionally used to treat bacterial infections, they operate by inhibiting folic acid synthesis in bacteria, impairing their ability to multiply. The necessity of sulphonamides is underscored by the persistent threat of bacterial infections globally, particularly in regions with high antibiotic resistance. Their application extends beyond human medicine, finding roles in veterinary medicine and even as precursors in chemical synthesis-further underscoring their versatile nature. End-use scope is broad, covering pharmaceutical companies, veterinary clinics, and research institutions focused on developing new antibacterial strategies.

KEY MARKET STATISTICS
Base Year [2023] USD 103.44 million
Estimated Year [2024] USD 108.52 million
Forecast Year [2030] USD 153.43 million
CAGR (%) 5.79%

Market growth for sulphonamides is driven by rising incidences of infectious diseases and the urgent need for effective antibiotics amid growing antimicrobial resistance. In particular, emerging markets in Asia and Africa present significant opportunities due to increasing healthcare investments and prevalence of infectious diseases. However, the market faces challenges such as regulatory hurdles and the threat of substitute drugs like newer antibiotic classes with fewer side effects. Additionally, public concern over the environmental impact of sulphonamides, which can persist in ecosystems through pharmaceutical waste, poses a constraint on their widespread use.

Innovation and research are pivotal, with potential breakthroughs in developing modified sulphonamides that retain efficacy while minimizing resistance development. Moreover, advances in targeted delivery systems could enhance their therapeutic index. The nature of the sulphonamide market is competitive yet dynamic, with ongoing need for solutions addressing antibiotic resistance-a call to action for investment in research toward low-resistance risk antibiotics. Companies should focus on strategic collaborations with academic institutions for cutting-edge research and partner with government health agencies to navigate regulatory landscapes. Ultimately, sustained market success hinges on balancing innovation with efficacy, safety, and environmental considerations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sulphonamides Market

The Sulphonamides Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases worldwide
    • Substantial availability of affordable sulfonamide drug formulations
    • Awareness regarding sulpha drugs and its therapeutic uses
  • Market Restraints
    • Side effects of sulphonamides
  • Market Opportunities
    • Increasing research & development in pharmaceutical companies
    • Rapidly advancing medical tourism industry
  • Market Challenges
    • Lack of regulatory structure in emerging economies

Porter's Five Forces: A Strategic Tool for Navigating the Sulphonamides Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sulphonamides Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sulphonamides Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sulphonamides Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sulphonamides Market

A detailed market share analysis in the Sulphonamides Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sulphonamides Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sulphonamides Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sulphonamides Market

A strategic analysis of the Sulphonamides Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sulphonamides Market, highlighting leading vendors and their innovative profiles. These include AA Pharma Inc., Abbott Laboratories, AbbVie Inc., Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Cipla Ltd., F. Hoffmann La Roche Ltd., Fera Science Limited, GlaxoSmithKline PLC, NorthStar Rx LLC, Novartis AG, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Sulphonamides Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Form, market is studied across Capsule, Liquid, Powder, and Tablets.
  • Based on Route of Administration, market is studied across Oral and Topical.
  • Based on Distribution Channel, market is studied across Online-Store Retailers and Store-Based Retailers.
  • Based on Application, market is studied across Gastrointestinal Tract Infection, Respiratory Tract Infection, Skin Infections, and Urinary Tract Infection.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases worldwide
      • 5.1.1.2. Substantial availability of affordable sulfonamide drug formulations
      • 5.1.1.3. Awareness regarding sulpha drugs and its therapeutic uses
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects of sulphonamides
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research & development in pharmaceutical companies
      • 5.1.3.2. Rapidly advancing medical tourism industry
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of regulatory structure in emerging economies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Sulphonamides Market, by Form

  • 6.1. Introduction
  • 6.2. Capsule
  • 6.3. Liquid
  • 6.4. Powder
  • 6.5. Tablets

7. Sulphonamides Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Topical

8. Sulphonamides Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Online-Store Retailers
  • 8.3. Store-Based Retailers

9. Sulphonamides Market, by Application

  • 9.1. Introduction
  • 9.2. Gastrointestinal Tract Infection
  • 9.3. Respiratory Tract Infection
  • 9.4. Skin Infections
  • 9.5. Urinary Tract Infection

10. Americas Sulphonamides Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Sulphonamides Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Sulphonamides Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AA Pharma Inc.
  • 2. Abbott Laboratories
  • 3. AbbVie Inc.
  • 4. Bausch Health Companies Inc.
  • 5. Cadila Pharmaceuticals Ltd.
  • 6. Cipla Ltd.
  • 7. F. Hoffmann La Roche Ltd.
  • 8. Fera Science Limited
  • 9. GlaxoSmithKline PLC
  • 10. NorthStar Rx LLC
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. Viatris Inc.
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦